[9] Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS guidelines for the management of valvular heart disease[J]. Eur Heart J, 2022, 43(7):561-632. DOI: 10.1093/eurheartj/ehab395. [10] García-Cabrera E, Fern...
baumgartner h, falk v, bax jj, et al. 2017 esc/eacts guidelines for the management of valvular heart disease [j]. eur heart j, 2017, 38(36): 2739-2791. [7] hindricks g, potpara t, dagres n, et al. 2020 esc guidelines for the diagnosis...
2.1 WHY DO WE NEED NEW GUIDELINES ON VALVULAR HEART DISEASE? Since the publication of the previous version of the guidelines on the management of valvular heart disease (VHD) in 2017, new evidence has accumulated, particularly on the following topics: Epidemiology: the incidence of the ...
Sex related differences in frequency, management and outcome of severe native valvular heart disease. Results from the ESC-EORP Valvular Heart Disease II survey ESC-EORP瓣膜性心脏病II调查结果:严重先天性瓣膜性心脏病的发病率、治疗和转归的性别差异 人工智能的注册、观测和其他研究 北京时间:8月30日 20...
No substantial updates were noted with respect to prosthetic valves or heart disease and pregnancy. The most important take away: the integral role of the heart team in the management of valvular heart disease! Given the rapid developments in this field, the guidelines will ...
valvular heart disease? 2023 American College of Cardiology FoundationValvular heart disease (VHD) is common and poses important challenges from the standpoints of diagnosis and therapeutic management. Clinical practice guidelines have been developed to help health care professionals to overcome these ...
2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) ...
RIVER: Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation RIVER研究:利伐沙班在瓣膜性心脏病合并心房颤动患者中的应用 EXPLORER-CN - Efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy ...
法洛四联症(TOF)具有以下4个特征:非限制型室间隔缺损(VSD),主动脉骑跨(但<50%),漏斗部(infundibular)/肺动脉瓣(valvular)/瓣上(supravalvular)右心室流出道梗阻(RVOTO)和/或肺动脉分支狭窄,以及因此导致的右心室肥厚(RVH)。TOF人群可分为综合征患者(约20%,例如:22q11微缺失综合征、唐氏综合征、Alagille综合...
1.Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). ...